ArticleBrain & spine2026
Tranexamic acid in spinal surgery: a stratified protocol from the surgeon's point of view.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intraoperative bleeding in spinal surgery remains a major concern, given its association with increased morbidity, prolonged hospitalization, and greater transfusion requirements. Tranexamic acid (TXA), a synthetic antifibrinolytic, has shown consistent efficacy in minimizing blood loss across diverse surgical contexts. Nevertheless, its application in spinal surgery must be individualized, taking into account bleeding risk, surgical complexity, and patient comorbidities. Research question: Following the creation of a dedicated Spine Unit, our objective was to design and validate a protocol for TXA administration and blood transfusion (BT) specific to spinal procedures. Materials and methods: We retrospectively reviewed 1223 spinal surgeries in 1059 patients aged over 13 years, conducted from April 2018 to April 2023. TXA use was guided by a stratified bleeding risk model incorporating surgical approach, use of minimally invasive spinal surgery (MISS), number of treated levels, instrumentation, reoperations, and diagnosis of complex spine surgery (CSS). Preoperative variables included hemoglobin level, anticoagulant/antiplatelet therapy, and coagulopathy. Outcomes assessed were transfusion needs, hemoglobin drop, estimated blood loss (EBL), complications, infections, length of stay, and mortality. Propensity scores (c-statistic = 0.756) and standardized morbidity ratio weighting addressed treatment selection bias. Results: TXA was significantly associated with non-MISS procedures involving instrumentation or high-bleeding-risk conditions such as metastatic tumours or deformities. EBL >500 mL increased the odds of TXA use 6.5-fold. TXA was not linked to thromboembolic or renal complications. Transfusion was associated with high-risk diagnoses, infections, prolonged aPTT, multilevel surgery, and EBL >500 mL, and predicted worse outcomes, including longer stays and higher mortality. TXA significantly reduced mortality (OR = 0.25). Discussion and conclusions: Our findings support a stratified TXA protocol incorporating patient- and procedure-related risk factors. Such an approach enhances perioperative safety, reduces transfusion requirements, and improves survival in high-risk spinal surgeries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.